Thomassen Mary Jane, Barna Barbara P, Malur Achut G, Bonfield Tracey L, Farver Carol F, Malur Anagha, Dalrymple Heidi, Kavuru Mani S, Febbraio Maria
Program in Lung Cell Biology and Translational Research, Division of Pulmonary and Critical Care Medicine, East Carolina University, Greenville, NC, USA.
J Lipid Res. 2007 Dec;48(12):2762-8. doi: 10.1194/jlr.P700022-JLR200. Epub 2007 Sep 11.
Patients with pulmonary alveolar proteinosis (PAP) display impaired surfactant clearance, foamy, lipid-filled alveolar macrophages, and increased cholesterol metabolites within the lung. Neutralizing autoantibodies to granulocyte-macrophage colony-stimulating factor (GM-CSF) are also present, resulting in virtual GM-CSF deficiency. We investigated ABCG1 and ABCA1 expression in alveolar macrophages of PAP patients and GM-CSF knockout (KO) mice, which exhibit PAP-like pulmonary pathology and increased pulmonary cholesterol. Alveolar macrophages from both sources displayed a striking similarity in transporter gene dysregulation, consisting of deficient ABCG1 accompanied by highly increased ABCA1. Peroxisome proliferator-activated receptor gamma (PPARgamma), a known regulator of both transporters, was deficient, as reported previously. In contrast, the liver X receptor alpha, which also upregulates both transporters, was highly increased. GM-CSF treatment increased ABCG1 expression in macrophages in vitro and in PAP patients in vivo. Overexpression of PPARgamma by lentivirus-PPARgamma transduction of primary alveolar macrophages, or activation by rosiglitazone, also increased ABCG1 expression. These results suggest that ABCG1 deficiency in PAP and GM-CSF KO alveolar macrophages is attributable to the absence of a GM-CSF-mediated PPARgamma pathway. These findings document the existence of ABCG1 deficiency in human lung disease and highlight a critical role for ABCG1 in surfactant homeostasis.
肺泡蛋白沉积症(PAP)患者表现出表面活性剂清除受损、肺泡巨噬细胞呈泡沫状且充满脂质,以及肺内胆固醇代谢产物增加。同时还存在针对粒细胞-巨噬细胞集落刺激因子(GM-CSF)的中和自身抗体,导致实际上的GM-CSF缺乏。我们研究了PAP患者和GM-CSF基因敲除(KO)小鼠肺泡巨噬细胞中ABCG1和ABCA1的表达,GM-CSF KO小鼠表现出类似PAP的肺部病理改变且肺内胆固醇增加。来自这两种来源的肺泡巨噬细胞在转运蛋白基因失调方面表现出惊人的相似性,即ABCG1缺乏伴ABCA1高度增加。如先前报道,过氧化物酶体增殖物激活受体γ(PPARγ),这两种转运蛋白的已知调节因子,缺乏。相反,同样上调这两种转运蛋白的肝X受体α高度增加。GM-CSF治疗在体外增加巨噬细胞中ABCG1的表达,在体内增加PAP患者巨噬细胞中ABCG1的表达。通过慢病毒-PPARγ转导原代肺泡巨噬细胞使PPARγ过表达,或用罗格列酮激活,也增加ABCG1的表达。这些结果表明,PAP和GM-CSF KO肺泡巨噬细胞中ABCG1缺乏归因于GM-CSF介导的PPARγ途径缺失。这些发现证明了人类肺部疾病中存在ABCG1缺乏,并突出了ABCG1在表面活性剂稳态中的关键作用。